Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily-Reference-Cited by-同舟云学术

Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily

Published:2018-04-10 Issue:7 Volume:2 Page:821-824
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Moskowitz Craig H.¹

Affiliation:

1. Division of Hematologic Oncology, Lymphoma Service, and Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and Department of Medicine, Weill Cornell Medical College, New York, NY

Abstract

Abstract This article has a companion Point by Peggs.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/7/821/880612/advances011130.pdf

Reference29 articles.

1. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation;Genadieva-Stavrik;Ann Oncol,2016

2. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation;Sureda;Haematologica,2012

3. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma;Peggs;J Clin Oncol,2011

4. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory hodgkin lymphoma;Wilke;Int J Radiat Oncol Biol Phys,2017

5. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?;Kahn;Int J Radiat Oncol Biol Phys,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances;International Journal of Molecular Sciences;2023-06-13

2. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series;Tumori Journal;2022-04-20

3. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes;Journal of Personalized Medicine;2022-01-18

4. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center;Pathology and Oncology Research;2021-07-27

5. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment;Bone Marrow Transplantation;2019-08-21